These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33404387)

  • 1. Efficacy of sublingual immunotherapy tablets in dust mite and pollen allergy.
    Bisyuk Y; DuBuske I; DuBuske LM
    Allergy Asthma Proc; 2021 Jan; 42(1):36-42. PubMed ID: 33404387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of respiratory allergy with allergy immunotherapy tablets.
    Bachert C
    Allergy; 2011 Jul; 66 Suppl 95():57-9. PubMed ID: 21668858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects.
    Szépfalusi Z; Bannert C; Ronceray L; Mayer E; Hassler M; Wissmann E; Dehlink E; Gruber S; Graf A; Lupinek C; Valenta R; Eiwegger T; Urbanek R
    Pediatr Allergy Immunol; 2014 Dec; 25(8):788-95. PubMed ID: 25406682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tablet-based sublingual immunotherapy for respiratory allergy.
    Prieto L
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():30-35. PubMed ID: 29146015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for house-dust mite allergy.
    Nelson HS
    Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy.
    Bauer CS; Rank MA
    J Allergy Clin Immunol; 2014 Sep; 134(3):765-765.e2. PubMed ID: 25171871
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual sublingual immunotherapy with Japanese Cedar Pollen droplets and House Dust Mite tablets.
    Matsuoka T; Igarashi S; Kuroda Y; Fukano C; Natsui K; Doi-Ohashi K; Masuyama K
    Allergol Int; 2019 Oct; 68(4):533-535. PubMed ID: 30962053
    [No Abstract]   [Full Text] [Related]  

  • 9. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of specific immunotherapies for house dust mite allergies.
    Moingeon P
    Expert Rev Vaccines; 2014 Dec; 13(12):1463-73. PubMed ID: 25187166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
    Mösges R; Ritter B; Kayoko G; Allekotte S
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect and the analysis of the influence factors of sublingual immunotherapy on patients with pharyngitis and allergy to house dust mite].
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Oct; 28(19):1511-3. PubMed ID: 25775760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical case of anaphylaxis with sublingual immunotherapy: house dust mite allergen.
    Van Dyken AM; Smith PK; Fox TL
    J Allergy Clin Immunol Pract; 2014; 2(4):485-6. PubMed ID: 25017545
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of subcutaneous immunotherapy with standardized house dust mite extract for patients under the age of 5 years: A prospective cohort study.
    Hamada M; Saeki K; Tanaka I
    Allergol Int; 2021 Oct; 70(4):492-494. PubMed ID: 34108104
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of sublingual allergen immunotherapy.
    DuBuske L
    Allergy Asthma Proc; 2022 Jul; 43(4):272-280. PubMed ID: 35818141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual Versus Subcutaneous Immunotherapy as regards Efficacy and Safety in Respiratory Allergic Patients.
    Atta AH; Amer RM; Mesbah AE; Khater MW
    Egypt J Immunol; 2019 Jul; 26(2):65-78. PubMed ID: 31926496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.
    Klimek L; Mosbech H; Zieglmayer P; Rehm D; Stage BS; Demoly P
    Expert Rev Clin Immunol; 2016; 12(4):369-77. PubMed ID: 26788764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy.
    Schulten V; Tripple V; Aasbjerg K; Backer V; Lund G; Würtzen PA; Sette A; Peters B
    Clin Exp Allergy; 2016 Mar; 46(3):439-48. PubMed ID: 26436865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.